The first year of OMICSENS has yielded promising results, laying a strong foundation for achieving its ambitious objectives. Key advancements, boyond the state of the art, include the development of robust nanostructured metasurfaces, stable functionalization protocols for nanoparticles, and compact IR emitter arrays. These breakthroughs support the creation of the nano-photonic bio-sensor, capable of real-time multi-omics measurements and integration with organ-on-chip systems. Early-stage machine learning models for molecule identification further strengthen the project’s potential to provide precise and efficient diagnostic tools. The filing of two patents in the first year underscores the project's innovation and commercialization prospects.
The potential impacts of OMICSENS are far-reaching. In healthcare, the bio-sensor promises to revolutionize cancer prognosis by enabling timely and accurate detection of TKI resistance in NSCLC patients. It will pave the way for broader applications in other cancers and diseases, advancing personalized medicine and drug testing. By democratizing access to advanced diagnostics, OMICSENS is poised to reduce barriers to care, foster a patient-centered approach, and improve health outcomes worldwide. Its miniaturized, portable design also aligns with the growing demand for telehealth solutions, further enhancing its societal and economic impact.
To complete the development of the first OMICSENS bio-sensor prototype, fundamental research and the creation of a finalized design must still be undertaken. This includes refining the integration of key components, such as the metasurface, IR emitter arrays, microfluidics, and AI algorithms, into a cohesive, functional device. Once the prototype is completed, rigorous testing will be necessary to validate its performance, reliability, and clinical effectiveness. Following successful validation, production processes can be scaled, enabling the sensor to enter larger markets and address a broader range of diagnostic applications. This transition will mark a pivotal step in bringing OMICSENS from groundbreaking research to a transformative, widely accessible medical technology.
